Medtronic 670G Insulin Pump and the Impact on Glycemic Control, Quality of Life, and Compliance
NCT ID: NCT04329871
Last Updated: 2020-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2020-03-24
2021-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Glycemic Control in Type 1 Diabetes Patients Using Hybrid Closed Loop Insulin Pump Therapy (Medtronic 670G)
NCT04051632
MiniMed™ 670G System China Study for Type I Diabetic
NCT04663295
Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes
NCT01713348
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
NCT02463097
Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life
NCT04939766
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented History of Type 1 Diabetes Mellitus
* 3 months continuous use of the Medtronic 670g pump system
* given written informed consent
Exclusion Criteria
* Taking any other medication, other than the insulin used in the Medtronic 670g pump, to manage their diabetes
* having medical conditions or taking medications that would preclude subject involvement or affect the outcomes being measured, in the opinion of the Investigator
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Metabolic Research Institute, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barry S Horowitz, MD
Role: PRINCIPAL_INVESTIGATOR
Metabolic Research Institute, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Metabolic Research Institute
West Palm Beach, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
There are no Citations
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Individual Participant Data Set
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Company website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MetabolicRI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.